Work

Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities

Year: 2024

Type: article

Source: ACS Infectious Diseases

DOI: 10.1021/acsinfecdis.4c00025

Institutions: National Institutes of Health, Merck & Co., Inc., Rahway, NJ, USA (United States), National Institute of Allergy and Infectious Diseases, Colorado State University, Hackensack Meridian Health

Language: English

Topic: Tuberculosis Research and Epidemiology

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Bill and Melinda Gates Foundation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NHLBI Division of Intramural Research

Awards: G3448736570, G3531344918, National Institute of Allergy and Infectious Diseases - to contribute to the TB drug target regimen profile by delivering new hits and leads for TB drug discovery

OpenAlex ID: W4394015059

FWCI: 2.908

Cites: 38

Cited by: 9

Related to: 10